Bruce Lahn, PhD | Chief Scientist
Bruce obtained his BA from Harvard University and PhD from MIT. He has an extensive track record in both academia and industry, including chaired professorship at the University of Chicago and investigatorship at the Howard Hughes Medical Institute (HHMI), and founding or chief scientific advisory functions for a number of research institutions and successful biotech enterprises.
Bruce’s expertise span many fields including biotechnology, genetics, genomics, epigenetics, stem cell biology and evolution, and has over 100 publications and patents. His leadership in research and the biotech industry has also won him numerous awards and a reputation as a restless innovator and disruptor.
Kristofer Mussar, PhD, MBA | Chief Operating Officer
Kristofer Mussar graduated from University of Georgia with a PhD in Molecular Genetics where he focused on Epigenetics and Evolution. He simultaneously obtained his MBA from the Terry College of Business, being the first to do so, thereby opening the door for others at UGA to follow this path. Prior to this, he has multi-research backgrounds starting in Organic Chemistry and Structural Biology and evolving to Bioinformatics and Genomics where he developed algorithms to detect novel ncRNAs.
Kristofer is the Managing Director of VectorBuilder GmbH and COO of VectorBuilder Inc. Joining VectorBuilder in its inception, he quickly opened VectorBuilder GmbH a year after and has been running VB operations ever since. He has helped ignite the fast development of VectorBuilder and is a core leader in the senior management team.
Jason Ye, PhD | Chief Technology Officer
Jason joined Vectorbuilder as R&D director with a focus on developing and optimizing the manufacturing process and analytic methods for variant advanced therapies. He is now leading the CDMO team and in charge of the GMP manufacturing for vectors for clinical purposes.
Prior to joining VectorBuilder, Jason graduated with a PhD degree in Fudan University, and his research focused on the animal models and molecular mechanisms of genetic diseases.
Grace Yu, PhD | VP of Global Business
Grace received her PhD in Genetics at The University of Chicago where she studied estrogen gene regulation network in breast cancer using systems genomics approaches.
Since joining VectorBuilder in 2017, Grace has led the global product and marketing teams to expand VectorBuilder’s product portfolio from research vector services to one-stop gene delivery CRO and CDMO services, and has helped establish VectorBuilder Japanese and Korean websites. Meanwhile, she has been overseeing the global business and technical support coordination to successfully achieve VectorBuilder’s unique business model.
Tim Reid | Global Sales Director
Tim Reid joined VectorBuilder in 2020 bringing with him 20 years of business development experience. He also has 5 years of experience consulting with over 100 pharma service providers building and implementing BD strategies that significantly increased their market exposure and penetration.
At VectorBuilder, Tim has innovatively identified niches in the market and launched new products successfully. He has a proven track record of building highly successful sales and account management teams. Tim believes that corporate ethic, values and culture are imperative in building a successful company that meets and exceeds customer expectations, and he prides himself on building agile teams that reflect these convictions.
Christina McClure, PhD | Associate Sales Director of Europe, UK and Scandinavia
Christina completed her BSc and PhD at The University of Aberdeen generating novel AAVs to facilitate in vivo studies of specific neuronal cell types involved in working memory. She then carried on her academic career at The University of Edinburgh where she established AAV technology for in vivo research. Due to high demand, in 2014 the university funded her setting up a research facility designing and providing novel AAVs to researchers around the world. During this time she also was awarded multiple grants, including funding for market research from the BBSRC and £250,000 from the IBioIC to collaborate with a local biotech start up.
In 2018 she discovered VectorBuilder and decided to join the company, who she believes to be the emerging industry leader in a wide range of viral and nonviral gene delivery tools and services.